Ostatné · AXGN
AxoGen, Inc.
Fundamenty firmy Healthcare · Medical Devices · United States
Hodnotenie 0–10, vypočítané z údajov firmy
Analytici 10 hodnotení
silný nákup
- Najnižší cieľ
- 48,00
- Priemerný cieľ
- 53,70
- Najvyšší cieľ
- 58,00
- Potenciál
- +43,0 %
Odhad zisku na akciu (EPS)
| Obdobie | Odhad | Rozpätie | Pred rokom | Rast |
|---|---|---|---|---|
| tento štvrťrok | 0,13 | 0,08–0,16 | 0,12 | +6,2 % |
| budúci štvrťrok | 0,12 | 0,06–0,14 | 0,07 | +71,4 % |
| tento rok | 0,46 | 0,40–0,51 | 0,29 | +58,1 % |
| budúci rok | 0,69 | 0,48–0,89 | 0,46 | +51,0 % |
Odhad tržieb
| Obdobie | Odhad | Pred rokom | Rast |
|---|---|---|---|
| tento štvrťrok | 73,3 mil. | 60,1 mil. | +22,0 % |
| budúci štvrťrok | 78,7 mil. | 59,9 mil. | +31,4 % |
| tento rok | 283,2 mil. | 225,2 mil. | +25,8 % |
| budúci rok | 350,1 mil. | 283,2 mil. | +23,6 % |
Nákupy a predaje manažérov insider
| Kto | Čo | Hodnota | Dátum |
|---|---|---|---|
| Tyndall Joseph ADirector | predaj | 173 940 | 02.09. |
| Mcbride-Wendell Amy A.Director | predaj | 646 592 | 11.08. |
| Mcbride-Wendell Amy A.Director | uplatnenie opcií | 198 292 | 11.08. |
| Began Marc A.General Counsel | predaj | 3,2 mil. | 10.08. |
| Began Marc A.General Counsel | uplatnenie opcií | 550 800 | 10.08. |
| Weiler Kathy JohnsonDirector | predaj | 640 967 | 07.08. |
| Thomas Paul GDirector | iná transakcia | – | 18.06. |
| Mcbride-Wendell Amy A.Director | iná transakcia | – | 18.06. |
| Burke William P.Director | iná transakcia | – | 18.06. |
| Levine Alan M.Director | iná transakcia | – | 18.06. |
| Tyndall Joseph ADirector | iná transakcia | – | 18.06. |
| Weiler Kathy JohnsonDirector | iná transakcia | – | 18.06. |
Kto vlastní akcie
Blackrock Inc.8,22 %
Morgan Stanley5,11 %
First Light Asset Management, LLC5,11 %
Vanguard Capital Management LLC4,20 %
Polar Capital Holdings PLC2,79 %
Artemis Investment Management Llp2,60 %
Wellington Management Group, LLP2,59 %
Geode Capital Management, LLC2,56 %
O firme (popis z Yahoo Finance, anglicky)
Axogen, Inc., together with its subsidiaries, engages in the development and commercialization of the technologies used for peripheral nerve regeneration and repair worldwide. The company offers Avance Nerve Graft, a processed nerve allograft intended for the surgical repair of peripheral nerve discontinuities; Axoguard Nerve Connector, a coaptation aid used to align and connect severed peripheral nerve ends in a tensionless repair; and Axoguard Nerve Protector, a product used to protect and wrap damaged peripheral nerves and reinforce reconstructed nerve gaps. It also provides Axoguard HA+ Nerve Protector, a surgical implant for non-constricting protection of the peripheral nerves; Axoguard Nerve Cap, a porcine submucosa ECM product; Avive+ Soft Tissue Matrix, a multi-layer amniotic membrane allograft; and Avance Method, a technique to process Avance Nerve Graft from donated human peripheral nerve tissue. In addition, the company offers peripheral nerve tissue recovery and acquisition, and testing, as well as donor medical review and release, debridement and other processing steps, packaging, and sterilization. It provides its products to hospitals, surgery centers and military hospitals, calling on surgeons, including plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and certain oral and maxillofacial surgeons through independent in-country distributors. The company is headquartered in Alachua, Florida.
Názor AI
Krátke zhodnotenie trendu, správ a blížiacich sa udalostí.
Technické signály
- Prepredané – RSI 28 – po silnom poklese často nasleduje odraz
Odporúčania
K tomuto aktívu zatiaľ nemáme odporúčanie.
Predikcie
Žiadne predikcie.
Súvisiace správy
Žiadne správy so značkou AXGN.